Get the Stockscreener App
64.96
0.02%
-0.01
Alpine Immune Sciences Inc stock is currently priced at $64.96, with a 24-hour trading volume of 732.76K.
It has seen a -0.02% decreased in the last 24 hours and a +0.71% rose in the past month.
The chart indicates a potential bullish trend, as the stock is below the $64.96 pivot point. If it approaches the $64.95 support level, significant changes may occur.
Previous Close:
$64.97
Open:
$64.97
24h Volume:
732.76K
Market Cap:
$4.46B
Revenue:
$56.52M
Net Income/Loss:
$-36.84M
P/E Ratio:
-47.07
EPS:
-1.38
Net Cash Flow:
$-80.96M
1W Performance:
+0.22%
1M Performance:
+0.71%
6M Performance:
+413.11%
1Y Performance:
+657.99%
1D Range:
$64.95
$64.98
52W Range:
$8.33
$64.98
Alpine Immune Sciences Inc Stock (ALPN) Company Profile
Name
Alpine Immune Sciences Inc
Sector
Industry
Phone
206-788-4545
Address
201 Elliott Avenue West, Suite 230, Seattle, WA
Alpine Immune Sciences Inc Stock (ALPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-18-23 | Initiated | Berenberg | Buy |
| Oct-17-23 | Initiated | Berenberg | Buy |
| Oct-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-19-23 | Initiated | Morgan Stanley | Overweight |
| Nov-21-22 | Initiated | SVB Leerink | Outperform |
| Dec-21-20 | Initiated | H.C. Wainwright | Buy |
| Aug-26-20 | Initiated | Cowen | Outperform |
View All
Alpine Immune Sciences Inc Stock (ALPN) Latest News
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Acquired by New York State Common Retirement Fund - Defense World
Defense World
Alpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at Wedbush - MarketBeat
MarketBeat
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
MarketBeat
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences - Alpine Immune Sciences (NASDAQ:ALPN) - Benzinga
Benzinga
Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 52-Week High at $64.96 - MarketBeat
MarketBeat
Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release - Yahoo Movies UK
Yahoo Movies UK
Alpine Immune Sciences Inc Stock (ALPN) Financials Data
Alpine Immune Sciences Inc (ALPN) Revenue 2024
ALPN reported a revenue (TTM) of $56.52 million for the quarter ending March 31, 2024, a +118.89% rise year-over-year.
Alpine Immune Sciences Inc (ALPN) Net Income 2024
ALPN net income (TTM) was -$36.84 million for the quarter ending March 31, 2024, a +41.99% increase year-over-year.
Alpine Immune Sciences Inc (ALPN) Cash Flow 2024
ALPN recorded a free cash flow (TTM) of -$80.96 million for the quarter ending March 31, 2024, a -6.76% decrease year-over-year.
Alpine Immune Sciences Inc (ALPN) Earnings per Share 2024
ALPN earnings per share (TTM) was -$0.64 for the quarter ending March 31, 2024, a +62.57% growth year-over-year.
About Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
4.27%
2.59%
Cap:
|
Volume (24h):